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Introduction

Vascular Ehlers-Danlos Syndrome (vEDS) is an autosomal-dominant connective tissue disorder
caused by heterozygous mutations in the COL3A1 gene 1 . Currently, loss of structural integrity of the extracellular matrix is believed to drive the signs and symptoms of this condition, including spontaneous arterial dissection and/or rupture, the major cause of mortality [2] [3] [4] .
Using novel mouse models of vEDS that carry heterozygous Col3a1 glycine substitutions, we
show that signaling abnormalities in the PLC/IP3/PKC/ERK pathway (Phospholipase C/Inositol 1,4,5-triphosphate/Protein Kinase C/Extracellular signal-regulated kinase) are major mediators of disease pathology and dissection. Treatment with pharmacologic agents that inhibit ERK1/2
and PKCb activation prevent death due to spontaneous aortic rupture. Additionally, we find that pregnancy-or puberty-associated accentuation of vascular risk, also seen in vEDS patients, is rescued by attenuation of oxytocin or androgen signaling, respectively. Taken together, our results provide the first evidence that targetable signaling abnormalities contribute to the pathogenesis of vEDS, highlighting unanticipated therapeutic opportunities.
Protection from aortic dissection in vEDS mice treated with hydralazine was abruptly lost around the time of sexual maturity (~50 days). While this was observed in both sexes, the effect was greatly exaggerated in male vs. female vEDS mice (25% vs. 60% survival at 100 days, respectively), suggesting a potential role for androgens (Fig. 3E, F ). In keeping with this hypothesis, we found that the addition of the androgen receptor antagonist bicalutamide, at the time of weaning, to male mice that had been receiving hydralazine, lead to 90% survival at 100 days of age (Fig. 3G ). Treatment with bicalutamide alone did not afford long-term protection from vascular dissection in vEDS mice (Fig. 3H) . The elevated risk of vascular rupture in male mice at puberty is also seen in male vEDS patients and has been vaguely attributed to events that attend the adolescent growth spurt 4, 23 . Incidence and severity of aneurysm/dissection is greater in males with MFS 24 and males with abdominal aortic aneurysm 25 suggesting that androgen signaling may play a broader role in aortic dissection, but the exact mechanism is still unclear [25] [26] [27] .
In anticipation of a reluctance to consider use of androgen receptor antagonists in young men with vEDS, we considered the potential use of spironolactone. Spironolactone is a diuretic that reduces adrenal androgen production, is a competitive antagonist of the androgen receptor and is used clinically to treat hyperandrogenism in the context of skin and hair disorders 28, 29 .
Spironolactone is commonly used in children of both genders for its diuretic effect and whereas males can experience mild gynecomastia and females can show menstrual irregularity, these effects are dose-and duration-dependent and are reversible with drug cessation. Initiation of treatment with hydralazine and spironolactone at 21 days of age in vEDS mice of both sexes achieved 100% survival at the end of the trial 60 days later, as compared to 45% survival in untreated animals (Fig. 3I ). Survival correlated with the status of ERK1/2 phosphorylation in the aortic wall, which was increased in vEDS mice, reduced in vEDS mice prior to sexual maturity upon treatment with hydralazine, increased in vEDS mice after sexual maturity despite ongoing treatment with hydralazine, but again reduced in sexually mature vEDS mice treated with both hydralazine and spironolactone (Fig. 3J, K ).
In women with vEDS, there is an estimated 12-25% lethality associated with pregnancy, historically attributed to hemodynamic stress 1, 30, 31 . We have previously shown that pregnancyassociated aortic dissection in MFS mice is largely driven by lactation-associated oxytocin release and oxytocin-induced PLC/IP3/PKC/ERK signaling 32 . In view of our data suggesting that over-activation of this pathway drives aortic dissection in vEDS mouse models, we hypothesized that pregnancy-associated vascular events in vEDS are driven by a mechanism similar to that observed in MFS mouse models.
We thus examined the effect of pregnancy and lactation on the survival of Col3a1 G209S/+ mice, which have a milder phenotype. In this mouse model, we found that pregnancy and lactation is associated with 54% lethality due to arterial dissection in the first 30 days postpartum, compared to 96% survival during this same time period in never-pregnant Col3a1 G209S/+ females (Fig. 4A) . Removal of the litter right after birth and consequent prevention of lactation was able to prevent dissection and death in vEDS Col3a1 G209S/+ mice, resulting in 100% survival in the postpartum period (Fig. 4B) , suggesting that the increased risk of aortic dissection was dependent on lactation. Moreover, as previously shown in a mouse model of MFS 32 , treatment with a specific oxytocin receptor antagonist 33 led to enhanced postpartum survival (~90%) (Fig.   4C ).
We next tested the effect of inhibitors of MEK/ERK and PKC activation in postpartum lactating female mice. Initiation of either MEK/ERK inhibition using trametinib or IP3/PKC inhibition using hydralazine in Col3a1 G209S/+ mice at the time of delivery resulted in 95% survival at day 30 postpartum, compared to 46% survival in untreated lactating vEDS mice (Fig. 4D, E) . The beneficial effect of these treatments correlated with a decrease in ERK activation, as measured immunoblotting of aortic lysates for ERK1/2 phosphorylation and analysis of gene expression of ERK target genes ( Fig. 4G-J) . Similar to what we observed in non-pregnant vEDS mice ( Supplementary Fig. 3 ), treatment with propranolol had no impact on survival in the postpartum period (Fig. 4F ). This suggests that despite the reduction in blood pressure and heart rate achieved with propranolol ( Supplementary Fig. 3 ), a current standard of care for pregnant women with vEDS, there was no demonstrable beneficial effect on survival in this mouse model.
Taken together, this data further supports the notion that excessive activation of the PLC/IP3/PKC/ERK signaling pathway drives aortic dissection in both pregnant and non-pregnant vEDS mice.
Our results provide the first evidence for a targetable signaling abnormality that contributes to the pathogenesis of vEDS and illustrate the promise of therapeutic strategies aimed at inhibition of the PLC/IP3/PKC/MEK/ERK axis of activation. It is notable that other vascular connective tissue disorders converge on the same pathway despite mechanistic differences in more proximal events (e.g. TGFb and AT1R activation in MFS mouse models). Additional work will be needed to elucidate the nature of outside-in cellular signaling that initiates with type III collagen deficiency, cross-talks with androgen signaling, and culminates in PKC/ERK activation and arterial dissection in vEDS.
Methods
Mice
All mice were cared for under strict adherence to the Animal Care and Use Committee of the Johns Hopkins University School of Medicine.
Generation of Col3a1 knock-in mice
To generate Col3a1 knock-in mice, we targeted the Col3a1 locus using CRISPR-Cas9
(clustered, regularly interspaced palindromic repeat-CRISPR-associated protein 9). Two singleguide RNA (sgRNA) sequences for each intended mutation (see Supplementary Table 1) were designed to target exon 39 or exon 7 of Col3a1 (NC_000067.6) using a gRNA CRISPR design tool (crispr.mit.edu). The gRNAs were predicted to have negligible off-target effects. The sgRNA was transcribed in vitro. The homology directed repair (HDR) template was purchased as a 4-nmol Ultramer (IDT, see Supplementary Table 1 ). For the Col3a1 G938D/+ mouse, the sgRNA, Cas9 (TriLink BioTechnologies), and HDR were co-injected into C57BL/6J zygotes (Johns Hopkins University Transgenic Core). For the Col3a1 G209S/+ mouse, the guide RNA sequences were ligated into the pX330 vector (Addgene#42230) according to Cong et al. 34 . Briefly, plasmid was linearized with BbsI (R3539S, New England Biolabs) and gRNAs were ligated into the restriction site and verified through Sanger sequencing. In vitro transcription of the cloned gRNAs was performed using MEGAscript T7 Transcription Kit (Life Technologies). The amplicon was purified with a PCR purification kit (Qiagen) and was used as a template for the IVT kit, according to the suggested protocol. All mice were maintained on a C57BL/6J
background (#000664, The Jackson Laboratory).
Mutation validation, Sanger sequencing, and Genotyping.
Bidirectional Sanger DNA sequencing assays were performed using primers designed 100 to 200 bp from the intended mutation to confirm correct insertion. PCR was performed using a DNA Engine Dyad thermal cycler (Bio-Rad). iProof High Fidelity PCR Master Mix (BioRad) was used in accordance with the manufacturer's instructions for each primer set. Cycle sequencing was performed using the BigDye Terminator v3.1 kit and an ABI 3730xl DNA Analyzer in accordance with the manufacturer's instructions (Life Technologies). Samples were purified using the QIAquick PCR Purification kit (Qiagen). After confirmation of the intended mutation, restriction enzymes were used to detect the presence or absence of the mutation. The G209S mutation leads to the loss of an AvaII cut site and the G938D mutation leads to the gain of a BamHI cut site (AvaII R0153L; BamHI-HF R3136S, New England Biolabs).
All mice found dead were assessed for cause of death by necropsy, noting in particular hemothorax and hemoperitoneum.
Echocardiography
Mice were imaged as previously described 12 . Briefly, echocardiograms were performed on awake, unsedated mice using the Visualsonics Vevo 660 V1.3.6 imaging system and a 30MHz
transducer. Three separate measurements of the maximal internal dimension at the aortic root and proximal ascending aorta were made from distinct captured images and averaged. All imaging and measurements were performed by a researcher who was blinded to genotype.
Measurements were normalized to weight, as the Col3a1 G938D/+ mice are significantly smaller than their Col3a1 +/+ littermates.
Histology
Mice were euthanized by isoflurane inhalation and the left common iliac artery was transected to allow for drainage. PBS (pH 7.4) and PBS containing 4% paraformaldehyde (PFA) was flushed through the left ventricle. The heart and thoracic aorta were removed en block and fixed in 4%
PFA overnight at 4 o C. Aortas were submitted for paraffin fixation and longitudinal sections 5 micrometers thick were mounted on glass slides and stained with hematoxylin & eosin (HE), Verhoeff-van Giesen (VVG), Masson's Trichrome, or Picrosirius red (PSR). Slides were imaged at 20x and 40x magnification using a Nikon Eclipse E400 microscope. Collagen content was determined by polarized PSR intensity 35 and elastin breaks were counted by a researcher blinded to genotype and treatment arm.
Electron Microscopy
Electron microscopy was performed as previously described 36 focusing on the proximal descending thoracic aortic wall.
RNAseq
RNA was isolated from the proximal descending thoracic aorta of three mice for each condition, flushed in PBS, and directly stored into TRIzol (Invitrogen). RNA was extracted according to manufacturer's instructions and purified using the PureLink RNA Mini Kit (Invitrogen). Library prep was performed using TruSeq Stranded Total RNA with Ribo-Zero (Illumina). Sequencing was run on an Illumina HiSeq2500 using standard protocols.
Bioinformatics
Illumina's CASAVA 1.8.4 was used to convert BCL files to FASTQ files. Default parameters were used. rsem-1.3.0 was used for running the alignments as well as generating gene and transcript expression levels. The data was aligned to "mm10" reference genome.
EBseq was used for Differential Expression analysis and default parameters were used 37 .
The networks and upstream regulator analyses were generated through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).
Western Blot
Mouse descending thoracic aortas (distal to the left subclavian branch) were harvested, snap frozen in liquid nitrogen, and stored at -80 o C until processed. Protein was extracted using an automatic bead homogenizer in conjunction with a Protein Extraction Kit (Full Moon Biosystems). All protein lysis buffers contained both PhosSTOP and cOmplete™, Mini, EDTAfree Protease Inhibitor Cocktail (Roche). Western blotting was performed using LI-COR buffer and species appropriate secondary antibodies conjugated to IR-dye700 or IRdye-800 (LI-COR Biosciences), according to the manufacturer's guidelines and analyzed using LI-COR Odyssey.
The following primary antibodies were used: anti-b-Actin (8H10D10) (Cell Signaling Technology, 3700), anti-phospho ERK1/2 (Cell Signaling Technology, 4370), anti-PKC (phospho S660) (Abcam, 75837).
Delivery of Medication
For drug trials in the G938D mutation, mice were initiated on medication at weaning and 
Blood Pressure Analysis
Blood pressures were measured by tail cuff plethysmography one week prior to completion of a study. Mice were habituated to the system prior to collection in which 10-15 measurements were obtained and averaged. e, quantification of pPKCb and pERK levels normalized to b-actin loading control comparing Col3a1 +/+ (n=6) to Col3a1 G209S/+ (n=6) and Col3a1 G938D/+ (n=8) aortas. Error bars show mean ± s.e. Asterisks signify significant differences using two-tailed Student's t-test (pERK/G209S
Statistical Analysis
T=2.053, DF=16; pPKC/G209S T=2.950, DF=10; pERK/G938D T=2.770, DF=13; *p<0.05) or
Mann-Whitney test (G938D/pPKC; *p<0.05) depending on Shapiro-Wilk normality tests. g, Kaplan-Meier survival curve comparing male Col3a1 G938D/+ (n=18) mice receiving hydralazine in the drinking water starting from birth and continuing for 3 months to male Col3a1 G938D/+ mice receiving hydralazine in the drinking water starting from birth and bicalutamide in the food starting from weaning and continuing for 2 months (n=10). Significant differences were calculated using Log-Rank (Mantel-Cox) analysis. Hydral = hydralazine; Bical = bicalutamide g, Kaplan-Meier survival curve comparing male Col3a1 G938D/+ (n=30) mice male Col3a1 G938D/+ mice receiving bicalutamide in the food starting from weaning and continuing for 2 months (n=10). Significant differences were calculated using Log-Rank (Mantel-Cox) analysis. Bical = bicalutamide; P21 = post-natal day 21
i, Kaplan-Meier survival curve comparing Col3a1 G938D/+ (n=34) mice to Col3a1 G938D/+ mice receiving hydralazine in the drinking water and spironolactone in the food starting from weaning and continuing for 2 months (n=16). Significant differences were calculated using Log-Rank Asterisks signify significant differences between treatment groups using two-way ANOVA for blood pressure (DF = 1, F =15.26) and Mann-Whitney test for pulse rate (**p<0.01).
i, blood pressure measurements for mice on atenolol. Error bars show mean ± s.e. Asterisks signify significant differences between treatment groups using two-way ANOVA for blood pressure (DF=1, F=5.90) and Student's t-test for pulse rate (****p<0.0001, t=20.12) j, blood pressure measurements for mice on amlodipine. Error bars show mean ± s.e. Asterisks signify significant differences between treatment groups using two-way ANOVA for blood pressure (DF=1, F=8.134) and Student's t-test for pulse rate (p=0.1511, t=1.569) Differences between treatment groups were calculated two-way ANOVA for blood pressure and 
